Homeostatic and Tissue Reparation Defaults in Mice Carrying Selective Genetic Invalidation of CXCL12/Proteoglycan Interactions. by Rueda, Patricia et al.
Homeostatic and Tissue Reparation Defaults in Mice
Carrying Selective Genetic Invalidation of
CXCL12/Proteoglycan Interactions.
Patricia Rueda, Ade`le Richart, Alice Re´calde, Pamela Gasse, Jose´ Vilar,
Coralie Gue´rin, Hugues Lortat-Jacob, Paulo Vieira, Franc¸oise Baleux, Fabrice
Chretien, et al.
To cite this version:
Patricia Rueda, Ade`le Richart, Alice Re´calde, Pamela Gasse, Jose´ Vilar, et al.. Home-
ostatic and Tissue Reparation Defaults in Mice Carrying Selective Genetic Invalidation of
CXCL12/Proteoglycan Interactions.. Circulation, American Heart Association, 2012, 126 (15),
pp.1882-95. <10.1161/CIRCULATIONAHA.112.113290>. <pasteur-00743099>
HAL Id: pasteur-00743099
https://hal-pasteur.archives-ouvertes.fr/pasteur-00743099
Submitted on 15 Apr 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1 
HOMEOSTATIC AND TISSUE REPARATION DEFAULTS IN MICE CARRYING, 
SELECTIVE, GENETIC INVALIDATION OF CXCL12/PROTEOGLYCAN 
INTERACTIONS 
 
Rueda et al: CXCL12/proteoglycan interactions in angiogenesis  
 
Patricia Rueda, PhD
 1*
,
 
Adèle Richart MsC
 2,3*
, Alice Récalde PhD
 2,3*
,
 
Pamela Gasse PhD
 1
, 
José Vilar PhD
 2,3
, Coralie Guérin MsC
 2,3
, Hugues Lortat-Jacob PhD
 4
, Paulo Vieira PhD
 5
, 
Françoise Baleux PhD
 6
, Fabrice Chretien MD, PhD 
7
, Fernando Arenzana-Seisdedos MD
 1!‡
, 
Jean-Sébastien Silvestre PhD
 2,3!  
 
1
Institut Pasteur, Unité de Pathogénie Virale, Département de Virologie, INSERM U819, 
Paris, France 
2
INSERM UMRS 970, Paris Cardiovascular Research Center, Paris, France 
3
Université Paris Descartes, Sorbonne Paris cité, Paris, France 
4
CEA, CNRS, Université Joseph Fourier – Grenoble 1, Institut de Biologie Structurale Jean-
Pierre Ebel, UMR 5075, 38000 Grenoble, France 
5
Institut Pasteur, Unité de Lymphopoièse. INSERM U688, Paris, France 
6
Institut Pasteur, Unité de Chimie des Biomolécules. Centre National de la Recherche 
Scientifique 2128, Paris, France 
7
Institut Pasteur, Unité Histopathologie Humaine et Modèles Animaux, Département 
Infection et Epidémiologie, Paris, France; Université Versailles Saint Quentin en Yvelines, 
Faculté de Médecine ; Assistance Publique – Hôpitaux de Paris, Hôpital Raymond Poincaré, 
Paris, France 
*Authors have equally contributed to this work 
 2 
!Authors have equally contributed to this work 
 
‡
Correspondence should be addressed to Fernando Arenzana-Seisdedos: INSERM U819; 
Unité de Pathogénie Virale; Département de Virologie ; Institut Pasteur ; 28, Rue du Dr. Roux 
; 75724 Paris Cedex  
 
Total word count: 6994 
 
Subject code: 129 
 3 
ABSTRACT 
Background. Interaction with heparan sulfate (HS) proteoglycans is supposed to provide 
chemokines with the capacity to immobilize on cell surface and extracellular matrix for 
accomplishing both tissue homing and signalling of attracted cells. However, the 
consequences of the exclusive invalidation of such interaction on the roles played by 
endogenous chemokines in vivo, remains unascertained.  
Methods and results. We engineered a mouse carrying a Cxcl12 gene (Cxcl12
Gagtm
) 
mutations that preclude interactions with HS structures while they do not affect CXCR4-
dependent cell-signalling of CXCL12 isoforms (!,",#). Cxcl12Gagtm/Gagtm mice develop 
normally, express normal levels of total and isoform-specific Cxcl12 mRNA and show 
increased counting of circulating CD34+ haematopoietic precursor cells. Following induced 
acute ischemia, a marked impaired capacity to support revascularization was observed in 
Cxcl12
Gagtm/Gagtm 
animals associated to a reduced number of infiltrating cells in the ischemic 
tissue despite the massive expression of CXCL12 isoforms. Importantly, exogenous 
administration of CXCL12#,  which binds HS with the highest affinity ever reported for a 
cytokine, fully restores vascular growth, while HS-binding CXCL12# mutants failed to 
promote revascularization in Cxcl12
Gagtm/Gagtm
 animals.
 
Conclusions. These findings prove the role played by HS-interactions in the functions of 
CXCL12 both in homeostasis and physiopathological settings and document originally the 
paradigm of chemokine-immobilisation in vivo. 
 
Keywords : Angiogenesis, Ischemia, Chemokines, Proteoglycans, CXCL12 
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INTRODUCTION 
Chemokines control the migration of a large array of cells, thus regulating function and 
homeostasis of a number of tissues. Glycosaminoglycans (GAG), the glycanic moiety of 
proteoglycans, are considered as the critical biological structure that determines the 
immobilisation of chemokines on the extracellular matrix and cell surfaces. Immobilisation 
provides chemokines with a robust anchoring against blood flow and, by restraining their 
diffusion, facilitates both the formation of local gradients and the synchronous coordination of 
motility and cell adhesion 
1
 
2
 
3
. 
Among GAG, chemokines bind preferentially to heparan sulfate (HS) through interactions 
either of canonical BBXB and BBBXXB (B, basic; X, any residue) or discontinuous cationic 
protein epitopes, with the negatively charged sulfated residues of HS 
4
. Although chemokine 
binding to GAGs has been well described from a biochemical point of view, the functional 
aspects of these interactions remain poorly understood and in vivo investigations to address 
the importance of chemokine-GAG interactions are limited. In some cases the experimental 
approach, like the administration of sulfated glycans competing exclusively with HS 
5
 or the 
genetic interference selectively inhibiting endothelial HS biosynthesis 
6
, have broad effects 
and would affect, beyond chemokines, the interaction of GAG with many other factors. In 
other cases, the overlapping or spatial proximity of chemokine domains involved in receptor-
mediated cell signalling and GAG-attachment has obscured interpretation and significance of 
the results obtained by exogenous administration of GAG-binding mutant chemokines with 
reduced agonist capacity 
7
. 
In this regard, CXCL12 is unique among chemokines for the spatial separation between the 
receptor- and HS-binding sites, localized on the opposite sides of the molecule 
8
, thus 
permitting the evaluation of the contribution of each domain to their biological functions.  
 5 
In mice three isoforms (CXCL12!,  CXCL12" and CXCL12#), that show an exceptional 
degree of interspecies conservation exceeding 95% homology for their amino-acid sequences, 
are generated  by  alternative  splicing 
9
 
10
. CXCL12" and CXCL12# contain the entire amino-
acid sequence (68Aa) of CXCL12! which encompasses the CXCR4-binding domain  and the 
protein core BBXB motif (K24H25L26K27) critically required for the HS-binding. 
CXCL12" (72Aa) and CXCL12# (98Aa) differs from CXCL12! by the addition of the last 
four and thirty Aa, respectively encoding one and four additional BBXB motifs. While 
CXCL12! and CXCL12" display  affinities for HS or heparin in the same range of magnitude 
(KD, 93 and 25nM, respectively), that of CXCL12#  is 1.5 nM and constitutes the strongest 
HS-affinity ever measured for a cytokine 
11
 
12
. This firm interaction with HS relies on the 
cooperativeness of the core and the high cationic C-ter domain of the chemokine,  where the 
four overlapping BBXB motifs of CXCL12#  mostly accounts for the slow off-rates from 
immobilized HS 
12
. 
We reported previously that neutralisation of the K24H25L26K27 cationic charge (K24S and 
K27S substitutions) is sufficient to drastically reduce binding to HS and complexing of 
CXCL12!  either with immobilized-heparin or HS 11 12 13 14.  Similarly,   O’Boyle et al 
recently reported that combined K24S and K27S in CXCL12", are  sufficient  to impede HS-
binding of this isoform on the apical surface of endothelial cells and promote a dramatic 
blood and delayed clearance as compared to the WT counterpart 
15
. To abrogate HS-binding 
of CXCL12#,   the combined  mutation of K24H25L26K27 and the C-ter four overlapping 
BBXB motifs is therefore required 
12
 
13
. Of note, while all these HS-binding CXCL12 mutants 
show a preserved global structure defined by Nuclear Magnetic Resonance 
11
 
12
 and are full 
CXCR4 agonists in vitro 
11
 
10
 
12
 
13
 
15
, they have only a marginal capacity to attract leukocytes 
or endothelial progenitor cells in vivo and are unable to immobilise and localise properly on 
 6 
GAG structures 
13
 
15
. Importantly, CXCL12 HS-binding mutants induce homologous CXCR4 
desensitisation thus neutralising the chemoattractant properties of CXCL12 WT molecules 
15
.  
CXCL12 binds both CXCR4 and CXCR7 
16
 
17
 
18
 
19
, is the only cognate ligand of CXCR4, and 
plays essential and non-redundant roles in organogenesis 
20
 
21
. CXCL12 is widely expressed 
by mesothelial, epithelial, endothelial and oteoblasts as well as bone marrow (BM) stromal 
cells 
22
 
23
 
24
. It acts in post-natal life as a key chemoattractant for haematopoietic progenitor 
cells (HPC) and leukocytes 
24
 
16
 
17
 and regulates the BM homing and retention/egress of 
haemotopoietic cells 
25
 
26
 as well as the basal trafficking and transendothelial migration of 
leukocytes 
27
 
28
 
29
. Aside from homeostasis, CXCL12 is involved both in tumorigenesis and 
cancer metastasis 
30
 and is a pathogenic factor in systemic disease like rheumatoid arthritis 
where it shows proangiogenic and inflammatory effects 
31
. In addition, CXCL12 plays a role 
of paramount importance as an essential and non-redundant factor involved in tissue 
remodelling, in particular in vascular regeneration 
32
.  
Overall, the structural characteristics and pleiotropic roles played by CXCL12 make it ideally 
suited for investigating how the interactions with GAG/HS modulate the biological role of a 
chemokine in vivo. To this aim, we engineered a transgenic mouse expressing a Cxcl12 gene 
where the critical sequences encoding CXCL12 domains involved in HS-binding are 
selectively invalidated while preserving intact the CXCR4-agonist potency and efficiency of 
the mutant proteins. The mutant mice show enhanced serum levels of free CXCL12 and an 
increased number of circulating leukocytes and CD34+ haematopoietic cells 
5
. Strikingly, and 
in keeping with the essential role played by CXCL12 in tissue repair, these mice display a 
dramatically reduced capacity to regenerate vascular growth following acute ischemia that is 
recovered by expression of WT CXCL12 demonstrating the importance of GAG binding for 
proper in vivo function. This is the first description to our knowledge of an animal model 
where the HS-binding capacities of an endogenous chemokine were genetically invalidated 
 7 
and the consequences of the selectively impaired function investigated both in homeostasis 
and physiopathological settings. 
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METHODS 
Experiments were conducted according to the French veterinary guidelines and those 
formulated by the European Community for experimental animal use (L358-86/609EEC). 
 
Chemokines: cDNA expression vectors and synthesis. Tissues were obtained by dissection 
of Cxcl12
Gagtm/Gagtm
 mice or WT littermates previously sacrificed by cervical dislocation. 
Bone marrow was recovered from right tibiae by the flushing procedure using 5ml PBS. Total 
RNAs were purified using the RNAeasy Kit (Qiagen), and Cxcl12 cDNAs were synthesized 
using 0.5"g of the corresponding RNAs with random hexamer. The isoform-specific Cxcl12 
cDNA corresponding to WT and Cxcl12
Gagtm/Gagtm 
mice were generated as described 
previously 
13
 using the Cxcl12 primers: forward common, 5’-cacccatggacgccaaggtcgtcgcc-3’ 
and the reverse, 5’-ttacttgtttaaagctttctccaggta-3’, 5’- tcacatcttgagcctcttgtttaaagc-3’and 5’-
ctagtttttccttttctgggcagcc-3’ for Cxcl12!  Cxcl12 and  Cxcl12#.    
The coding CXCL12#m2 DNA was derived by mutagenesis from the WT sequence. All of 
them were subcloned in a CMV-promoter driven pcDNA3 expression vector (InVitrogen). 
HEK293 cells were transfected with CXCL12-expression vectors to generate CXCL12-
containing cell supernatants. Chemically synthesized chemokines were generated and 
evaluated for their purity and concentration as previously described
11
. 
 
Cxcl12 knock-in and Cxcl12
Gagtm
 mouse generation. A 14.5 kb genomic DNA used to 
construct the targeting vector was first subcloned from a positively identified C57BL/6 BAC 
clone (Dr. A. Lu. iTl, Fresh Meadows, New York, USA). The AAG > TCG and AAA > TCT 
(aa: K > S) mutations within exon 2, as well as the stop codon TAG insertion in exon 4, that 
selectively prevents translation of CXCL12#  last 30Aa, were generated by 3-step PCR 
mutagenesis. The PCR fragments carrying mutations were then used to replace the WT 
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sequence using conventional subcloning methods. The long homology arm extends $6.6 kb 5’ 
to the first set mutations in exon 2. The LoxP/FRT-Neo cassette was inserted $2.2 kb 
downstream of the first set mutations, and $2.3 kb upstream of the second set mutations (stop 
codon insertion in exon 4) in intron 3-4. The short homology arm extends 3.3 kb 3’ to the 
second set mutations. The targeting vector (backbone, a 2.4 kb pSP72 based vector) was 
validated by restriction analysis and sequencing after each modification. Ten micrograms of 
the targeting vector was linearized by Cla I digestion and then transfected by electroporation 
of BA1 (C57BL/6 x 129/SvEv) hybrid embryonic stem cells. After selection with G418 
antibiotic, surviving clones were expanded for PCR analysis to identify recombinant ES 
clones and a secondary confirmation of positive clones identified by PCR was performed by 
Southern Blotting analysis. Targeted BA1 (C57BL/6 x 129/SvEv) hybrid embryonic stem 
cells were microinjected into C57BL/6 blastocysts. Resulting chimeras with a high percentage 
agouti coat colour were mated to wild-type C57BL/6 mice to generate F1 Cxcl12
Gagtm/wt
 
offspring. Tail DNA was analyzed by PCR to confirm the integration of the desired 
sequences. The obtained Cxcl12
Gagtm/wt
 animals, mice were crossed with transgenic 129sv 
PGK-Cre for LoxP/FRT-Neo cassette excision. Offspring that do not inherit PGK-CRE and 
delete LoxP/FRT-Neo cassette were selected and the colony was amplified. Identification of 
genotypes of mice encoding Cxcl12
Gagtm
 upon excision of Neo-cassette was performed by 
PCR with forward, 5'tgccagcataaagacactccg3' and reverse 5'cagcccttgaagtaatcactgc 3' primers. 
  
Characterisation of Cxcl12 mRNA and protein expression in normal and ischemic 
tissues. For quantitative real time PC, cerebellum, brain, thymus, heart and skeletal muscle 
tissues were obtained by dissection of Cxcl12
Gagtm/Gagtm
 mice or WT littermates. Bone marrow 
was recovered from right tibiae by the flushing procedure using 5ml PBS. Total RNAs were 
purified using the Rneasy Kit (Qiagen) according to the manufacturer instructions, and 
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cDNAs were synthesized using 0.5"g of the corresponding RNAs with random hexamer. 
Quantitative real time-PCR was performed in a Mix3005Tm QPCR System with a MxPro 
QPCR Software 3.00 (Stratagene, La Jolla, CA) and SYBR Green detection system, using the 
forward common primer 5#tgcccttcagattgttgcac3# and the reverse primers 
5#ccacggatgtcagccttcc3#, 5#cttgagcctcttgtttaaagctt3#, or 
5#gctagcttacaaagcgccagagcagagcgcactgcg3# for Cxcl12!, Cxcl12" or Cxcl12#, respectively. 
Mouse HPRT and GAPDH genes were used as controls. Quantitative analysis was then 
performed using the Livak method. 
For evaluating CXCL12 accumulation and localisation in muscle, frozen sections (7 "m) were 
incubated with CXCL12 mAb K15C (10µg/ml) antibodies, FITC-Griffonia Simplicifolia 
Agglutinin isolectin B4 (1:100, Sigma) and rabbit anti-mouse alpha smooth muscle actin 
(1:100, Abcam) at room temperature. Finally, sections were incubated with DAPI (1:10,000, 
Sigma). Alexa fluor 594 (Invitrogen, 1:100) and Cy5-labeled secondary antibodies (1:200, 
Jackson Immunoresearch) were then used to reveal CXCL12 and alpha actin-positive 
stainings, respectively 
Quantification of CXCL12 in mice blood serum was carried out using the DuoSet ELISA 
Development kit for mouse CXCL12 (R&D Systems, MN, USA). Blood was collected by 
cardiac puncture.  
 
Cell surface binding potential and chemotaxis assay. Evaluation of synthetic CXCL12 
chemokines adsorption on cell surfaces of CHO GAG-expressing cells and chemotaxis assay 
(human CD4+ T lymphocytes or human endothelial progenitor cells (EPC), were performed 
as described previously
11
 
13
. EPC were isolated from human umbilical cord blood and 
differentiated ex vivo, as previously described
33
. 
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Peripheral blood analysis. WT and Cxcl12
Gagtm/Gagtm
 mice (n=10) were killed and blood 
collected as described above and transferred to EDTA pre-treated tubes (Sarstedt). Then, 20"l 
of sample were collected using the disposable diluting pipette system of the BD Unopette 
procedure (BD, NJ, USA). Cells were stained using the Gr1-FITC, CD4-PB and CD34-PE 
antibodies or the matching control isotypes and analyzed in a BD FACS Canto Flow 
Cytometer (BD Bioscience). Eythrocytes and Thrombocytes were quantified by flow 
cytometry (Siemens ADVIA 120). 
 
Experimental model of surgically-induced hindlimb ischemia.  
Induction of ischemia and plasmids electrotransfert. Cxcl12
Gagtm/Gagtm
 mice and their wild-
type C57BL/6 littermate underwent surgical ligation of the proximal part of the right femoral 
artery, above the origin of the circumflexa femoris lateralis. 50"g of expression plasmids 
encoding for CXCL12!, CXCL12# or CXCL12#m2 were then injected into both tibial 
anterior and gastrocnemius muscles of the anesthetized mouse, as previously described
34
. 
Transcutaneous electric pulses (8 square-wave electric pulses of 200 V/cm, 20 ms each, at 2 
Hz) were delivered by a PS-15 electropulsator (Jouan) using two stainless steel plate 
electrodes placed 4.2 to 5.3 mm apart, at each side of the leg. The left leg was not ligated 
neither electrotransfered and was used as an internal control. In additional set of experiments, 
C57BL/6 mice with surgically-induced hindlimb ischemia and treated with expression 
plasmids also received intravenous injection of 1.10
5
 human EPC.  
Analysis of neovascularization. Post-ischemic neovascularisation was evaluated by three 
different methods, as previously described
34
. 
Microangiography. Mice were anesthetized (pentobarbital) and longitudinal laparotomy was 
performed to introduce a polyethylene catheter into the abdominal aorta and inject contrast 
medium (Barium sulphate, 1 g/mL). Angiography of hindlimbs was then performed and 
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images (two per animals) were acquired using a high-definition digital X-ray transducer. 
Images were assembled to obtain a complete view of the hindlimbs. 
Capillary and arteriole density analysis. Frozen tissue sections (7 "m) from calf muscle were 
incubated with rabbit polyclonal antibody directed against total fibronectin (dilution 1:50, 
Abcys) to identify capillaries and rabbit anti-mouse alpha smooth muscle actin (dilution 
1/100, abcam) to identify arterioles. The capillary-to-myocytes ratio was determined in both 
ischemic and non ischemic legs. 
Laser Doppler Perfusion Imaging. Briefly, excess hairs were removed by depilatory cream 
from the limb, and mice were placed on a heating plate at 37°C to minimize temperature 
variation. Nevertheless, to account for variables, including ambient light, temperature, and 
experimental procedures, perfusion was calculated in the foot and expressed as a ratio of 
ischemic to non ischemic legs. 
 
Analysis of cell infiltration in the ischemic tissue.  
To evaluate the number of infiltrating CD45.1-positive cells, 10
7
 mononuclear cells isolated 
from the bone marrow of CD45.1 mice were intravenously injected to Cxcl12
Gagtm/Gagtm
 mice 
and their wild-type C57BL/6 littermate, 1 day after femoral artery ligation. Five days after the 
injection, the ischemic gastrocnemius muscles were harvested, weighed, minced and digested 
in 450 U/ml Collagenase I, 125 U/ml Collagenase XI, 60 U/ml DNAse I and 60 U/ml 
hyaluronidase (Sigma Aldrich) for 1 hour at 37°C. After Ficoll separation, infiltrating cells 
were stained with CD45.1-PerCPCy5.5, CD34-APC and CXCR4-PE and analyzed using a 
FACS Aria (BD). 
To measure the number of infiltrating EPC, the ischemic gastrocnemius muscles were 
digested as described above. The number of cells being positive for "2-microglobuline anti-
human FITC (Biolegend, 1:200) and DAPI was then evaluated on a LSRII Flow Cytometer 
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(Becton Dickinson). In a third set of experiment, 10-week wild-type C57BL/6 mice 
underwent medullar aplasia by total body irradiation (9.5 gray). Bone marrow cells were then 
isolated from femurs and tibias of GFP C57BL/6 mice and intravenously injected in irradiated 
animals. After 8 weeks, mice underwent surgical ligation of the proximal part of the right 
femoral artery, as described above. The gastrocnemius muscles were then harvested 2 days 
after ischemia. Infiltrating circulating BM-derived GFP-positive cells were detected by 
fluorescent microscopy and their endothelial cell phenotype revealed by costaining with 
rhodamine Griffonia Simplicifolia Agglutinin isolectin B4 (1:100, Sigma) and their 
inflammatory phenotype by co-staining with rat anti-mouse Mac-3 (BD pharmingen, 1:300) 
and donkey anti-rat RITC (Jackson ImmunoReaserch, 1:200).  
 
Statistical Analysis. Statistical analysis were performed using StatView. Kruskall Wallis 
analysis of variance was used to compare each parameter. Bonferroni-corrected Mann-
Whitney tests were then performed to identify which group differences account for the 
significant overall Kruskall Wallis. Results were expressed as mean ± SEM. A value of 
p<0.05 was considered significant. 
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RESULTS 
We have engineered mice encoding a Cxcl12 gene carrying mutations (Figure 1A and S1) that 
drastically reduce CXCL12/HS interactions as deduced from biochemical and biophysical 
measurements and functional assays in vitro and in vivo 
11
 
12
 
13
 
15
. K24S and K25S point 
mutations were introduced in the critical HS-binding domain (encoded in the second exon) 
shared by the three CXCL12 isoforms (Figure S2(A)). Furthermore, a nonsense amber 
mutation was introduced in the fourth exon to prevent the translation of the distinctive, thirty-
last Aa of the highly cationic C-ter domain of CXCL12# (Figure S1(A)). We opted for this 
strategy to avoid unpredictable consequences in the expression of a heavily CXCL12# 
mutated protein carrying multiple substitutions in the overlapping C-ter BBXB motifs 
required for abrogating HS-binding of this isoform.  
The relative amounts of each mRNA isoform in Cxcl12
Gagtm/Gagtm 
were comparable to that of 
WT littermates (Figure 1C and S2(C)) while serum CXCL12 levels were markedly increased 
in mutant animals, likely as a consequence of the mutant chemokines to immobilise on HS 
structures (Figure 1D). Expression and functional analysis of Cxcl12
Gagtm/Gagtm
 cDNA 
isoforms confirmed their preserved CXCR4-agonist capacities (Figure S3(D)). 
Cxcl12
Gagtm/Gagtm
 mice were both viable and fertile. Extensive macroscopic and histologic 
analysis did not reveal any detectable anatomic abnormalities in the Cxcl12
Gagtm/Gagtm
 mice. 
Micro photos corresponding to tissue preparations of WT and Cxcl12
Gagtm/Gagtm
 BM and 
cerebellum, which development is affected in Cxcl12 and Cxcr4 knock-out animals, as well as 
skeletal muscle, are shown in Figure 1B.  
No significant differences in the composition of blood, BM and CD34+ HPC were observed 
between WT and mutant animals (data not shown). Interestingly, whereas the number of BM 
haematopoietic cell subpopulations was similar in WT and Cxcl12
Gagtm/Gagtm 
mice, mutant 
animals displayed higher numbers of circulating total leukocytes, granulocytes and CD34+ 
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cells (Figure 1E) and no significant differences for both T and B lymphocytes. The number of 
erythrocytes (10.72±0.33/mm
3
 versus 10.32±0.31/mm
3
, n=6) and that of platelets 
(944±132/mm
3
 versus 1029±197/mm
3
, n=6)
 
in WT and Cxcl12
Gagtm/Gagtm 
mice, respectively, 
were similar. 
CXCL12 regulates both the tissue homing and survival of circulating tissue-specific 
progenitors, HPC and BM-stromal stem cells 
32
 
35
, triggers inflammatory cells infiltration and 
is required for the peri-endothelial  retention of circulating, BM-derived myeloid cells
36
 
32
 
35
. 
These findings prompted us to assess the role of CXCL12/GAG interactions in the 
regenerative process following acute regional ischemia.  
We observed that in both WT and Cxcl12
Gagtm/Gagtm 
mice, hindlimb-ischemia induced massive 
transcription and expression of Cxcl12 isoforms (Figure 2A). Kinetic analysis of mRNA 
levels showed that Cxcl12 isoforms expression enhanced by day 4 post-ischemia and returned 
to basal levels by day 21 (Figure 2A). The expression ratio between the Cxcl12 isoforms 
varies between different tissues (Figure S2(D)). Of interest, CXCL12# was the most abundant 
isoform in both the normal and ischemic muscle (Figure 2B). We also determined that 
CXCL12 was expressed in ischemic capillary structure and, in both WT and Cxcl12
Gagtm/Gagtm 
mice, is co-localized with isolectin B4 staining, a specific marker of endothelial cells (Figure 
2C). In addition, CXCL12 expression was also detected in number of arterioles, as revealed 
by the co-staining between CXCL12 and alpha-smooth muscle actin (Figure 2D). 
It is of note that Cxcl12
Gagtm/Gagtm 
mice displayed a markedly impaired capacity to support 
efficient post-ischemic revascularization in a model of hindlimb ischemia. Indeed, laser 
Doppler imaging showed a reduced paw perfusion in ischemic hind limb of Cxcl12
Gagtm/Gagtm 
as compared to WT animals, as early as day 14 after the onset of ischemia (Figure 3A). 
Angiographic scores obtained by microangiographic analysis revealed that vessel density was 
hampered by 30% in ischemic muscle of Cxcl12
Gagtm/Gagtm 
mice in reference to that of WT 
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animals (Figure 3B). Furthermore, analysis of post-ischemic frozen calf muscle samples 
showed that regeneration of both capillary and arteriole vessels were reduced in 
Cxcl12
Gagtm/Gagtm
 animals by up to 44% and 55%, respectively as compared to WT animals 
(Figure 3C and 3D).  
As previously mentioned, CXCL12/CXCR4 interactions are involved in the recruitment 
and/or the retention of circulating cells in the ischemic tissue. To gain further insights into the 
cellular and molecular mechanisms associated with the reduction of post-ischemic vessel 
growth in Cxcl12
Gagtm/Gagtm 
mice, we analyzed the ability of circulating cells to home to 
ischemic tissues in Cxcl12
Gagtm/Gagtm
 animals. CD45.1-positive cells were intravenously 
injected one day after the onset of ischemia, and their number and fate were analysed in the 
blood and in the ischemic tissue, 6 days after ischemia, a time point associated with a marked 
upregulation of transcription and expression of Cxcl12 isoforms. The number of CD45.1+, 
CD45.1+/CD34+ and CD45.1+/CXCR4+ was higher in the blood of Cxcl12
Gagtm/Gagtm
 animals 
compared to that of WT mice. In contrast, the percentage of CD45.1+/CD34+ and 
CD45.1+/CXCR4+ was decreased in the ischemic muscle of Cxcl12
Gagtm/Gagtm
 animals 
compared to that of WT mice (Figure 4A, B). As a consequence, the post-ischemic 
inflammatory response, a key component of ischemic tissue remodelling is affected in our 
experimental conditions and we showed that the number of Mac3-positive cells was reduced 
in ischemic leg of Cxcl12
Gagtm/Gagtm 
mice compared to WT littermates (Figure 4C).  
 
The predominant expression of CXCL12# in muscle and in particular its massive 
accumulation in ischemic tissues, suggests that this isoform might play a critical role in 
neovascularisation through an HS-binding dependent mechanism. Thus, if the angiogenic 
default observed in Cxcl12
Gagtm/Gagtm 
was due to the selective invalidation of HS-binding 
capacity of Cxcl12 products, exogenous administration of wild type CXCL12 proteins with 
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full HS-binding activity, should restore vascular regeneration in ischemic tissues with the 
highest efficiency as compared. 
To assess this hypothesis we first compared the capacity of both WT CXCL12! and 
CXCL12#, which differ notably for their affinity capacity to bind cell surface in a GAG-
dependent manner, to induce post-ischemic vascular regeneration in control animals. 
Electrotransfered expression of DNA plasmids encoding for CXCL12! or CXCL12# (Figure 
5A), revealed a dramatically increased potency of CXCL12# to promote neovascularisation as 
evaluated by tissue perfusion, angiographic score, capillary density and attraction of 
inflammatory macrophages in the ischemic tissue (Figure 5B, 5C, 5D and 5E). To bring direct 
and formal evidence that the superior efficiency of CXCL12# was actually related to the 
interaction of the chemokine with HS, we evaluated the pro-angiogenic capacities of 
CXCL12#  and   mutant  CXCL12#m2 which carries the K24S and K27S substitutions 
combined with the neutralisation of nine of the seventeen positively charged residues 
encompassed in the C-ter domain of this isoform 
12
 
13
 (Figure S3(A)). CXCL12#m2 displays 
no detectable HS-binding to cell surface HS whereas it activates CXCR4 with preserved 
efficiency and even with increased potency as compared to the WT control (Figure S3 (B,C)) 
and as we reported previously
13
. Our findings unambiguously proved that while CXCL12! 
and CXCL12# showed pro-angiogenic efficiency correlating with their affinities for HS, 
CXCL12#m2 failed to induce post-ischemic vessel growth beyond baseline 
levels  (Figure 5B, C and E).  
To further investigate the mechanism of the increased pro-angiogenic effect of CXCL12#,  we  
compared the capacity of each isoform to regulate both the number of cells infiltrating the 
ischemic tissue and their fate. To this aim, hindlimb ischemia was induced in mice that has 
been lethally irradiated and reconstituted with BM-derived cells isolated from GFP+ mice. 
Electrotransfer of CXCL12$ plasmid enhanced by 300% and 150% the number of GFP+ cells 
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infiltrating the ischemic muscle compared to mice treated with empty plasmid or 
CXCL12!, respectively (Figure 6A). The failure of CXCL12$m2 to induce a significant 
effect further proved the involvement of an HS-dependent mechanism in the robust 
neovascularisation induced by CXCL12$. Of note, the percentage of GFP
+
/BS1-lectin
+
 cells 
of the endothelial lineage, and that of GFP
+
/Mac3
+
 revealing the macrophage phenotype, were 
similar in mice treated with CXCL12$ or CXCL12!. Further experiments using human 
endothelial progenitor cells (EPC) labelled with CFSE revealed that CXCL12#,  but  not  
CXCL12#m2, increased the number of EPC infiltrating ischemic hindlimb muscle (day 4 pos-
ischemia) by 150% and subsequently vessel growth by roughly 50% (day 14 post-ischemia) 
when compared to mice treated with CXCL12! (Figure S4).  
Collectively, these results suggest that CXCL12# regulates the accumulation of BM-derived 
cells in ischemic tissues with the highest efficiency, in comparison to CXCL12!, and in a 
strictly HS-dependent manner, while it does not differ from CXCL12! regarding induction of 
cell differentiation. The increased number of EPC homing to the injured muscle early after 
ischemia permits to ascribe its prominent pro-angiogenic effect to a primary attraction of 
endothelial cell precursors.  
Finally, to demonstrate that the deficient neoangiogenesis observed in Cxcl12
Gagtm/Gagtm 
animals was related to the expression of CXCL12 HS-binding mutants and their inability to 
promote efficient vascular reparation, we electrotransfered a plasmid encoding WT 
CXCL12#   plasmid in the ischemic hindlimb. Expression of this isoform virtually normalized 
vascular regeneration in ischemic tissues as proved by the significant increase in both vessel 
density and infiltration of inflammatory macrophages (Figure 7). This finding conclusively 
links the default of tissue reparation observed in these animals to the reduced capacity of 
mutant CXCL12 proteins to form complexes with HS proteoglycans.  
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DISCUSSION  
The animal model we have engineered allows the selective characterization of proteoglycan-
chemokine interactions in vivo, separately from interactions of a defined chemokine to its 
specific receptor. Cxcl12
Gagtm/Gagtm 
mice exhibit normal expression of isoform-specific Cxcl12 
mRNAs encoding for CXCR4-agonist chemokines. No detectable developmental anomalies 
were observed in Cxcl12
Gagtm/Gagtm 
animals. This is in sharp contrast to Cxcl12- and Cxcr4-
deficient mice, which show in both cases abnormal haematopoiesis and multiple 
organogenesis default associated to perinatal mortality
20
 
21
 
37
, and to Cxcr7- knock-out mice, 
which show disrupted cardiac development
38
. Manifold reasons could explain the lack of 
detectable anatomic anomalies in the mutant animals. First, the preserved expression levels of 
total and isoform specific Cxcl12 mRNA in Cxcl12
Gagtm/Gagtm 
mice tissues. Second, the intact 
cell signaling capacities of mutant chemokines leading to orientated cell migration, as 
previously shown for mutated CCL19 and CCL21 
1
. Third, the oligosaccharidic HS structure 
recognized by CXCL12, which remains unknown, could not feature during embryogenesis the 
high affinity CXCL12 binding site, thus explaining the lack of observed effects. In this line, it 
has been proved a binding specificity switch of brain HS proteoglycans from FGF-2 to FGF-1 
39
, demonstrating that indeed the binding capacity of embryonic HS for a given protein is not 
necessarily present, and is acquired during development. 
The Cxcl12
Gagtm/Gagtm 
mice nevertheless display a subtle anomaly revealing an increased 
number of circulating white blood cells, including CD34+ HPC. This phenomenon could be 
explained by a reduced attraction/retention in lymphoid tissues and is probably related to 
impaired HS-dependent tissue adhesiveness of the CXCL12 mutant proteins 
15
 
5
. Given the 
crucial role played by CXCL12 and CXCR4 in both the homing of haematopoietic cells to the 
BM
25
 
26
, the inability of the HS-binding CXCL12 mutants to adhere to the cell surface and the 
surrounding extracellular matrix of CXCL12-producing stromal cells, forming CXCL12-BM 
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niches 
40
 could facilitate their egress from the BM. In this regard, the accumulation of 
circulating CD34+ cells, which normally reside in BM
41
, strongly argues in favour of reduced 
retention of these cells in BM. The BM egress of the mature leukocytes could also be due to 
the same mechanism. Alternatively, the increased number of these cells in the periphery could 
be ascribed to the gradient generated by the blood accumulation of free, HS-binding disabled 
CXCL12 proteins and/or their failure to firmly immobilize on the apical surface of sinus and 
post-capillary endothelial cells 
13
 
15
 that would inhibit the return of leukocytes to the BM 
42
.  
Whereas basal coronary flow were impaired in Cxcr4(+/-) mice, paralleled by reduced 
angiogenesis and myocardial vessel density, we did not detect changes in the basal number of 
capillary and arterioles in skeletal muscle of Cxcl12
Gagtm/Gagtm 
animals 
43
. In contrast, 
Cxcl12
Gagtm/Gagtm 
animals show a marked default in angiogenesis and neovascularisation of 
ischemic tissues, revealing a biological role for CXCL12/GAG interactions in tissue repair 
after ischemia. It has been previously reported that recruitment of CXCR4-positive progenitor 
cells to regenerating tissues is mediated by hypoxic gradients via HIF-1-induced expression of 
CXCL12 
32
. Furthermore, CXCL12 attracts EPC, induces angiogenesis and increases the 
number of newly formed vessels and blood flow in models of hindlimb ischemia when 
overexpressed, either alone 
44
 or combined with cell therapy 
45
. Recruitment and retention of 
BM-derived circulating inflammatory cells mediated by CXCL12 participates to vascular 
remodelling and arteriole growth 
36
. In addition, CXCL12 seems to have a direct effect on 
migration of smooth muscle cells and smooth muscle progenitor cells 
46
.  
However, all previous studies focussed on deciphering the capacity of CXCL12! to promote 
angiogenesis, without dissecting the respective contribution of receptor activation and GAG-
binding. Furthermore, only the therapeutic capacity of exogenous WT chemokines was 
investigated, while the role played by endogenous CXCL12/GAG interactions in the 
spontaneous post-ischemic recovery remained unknown.  
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The defective post-ischemic neovascularisation observed in Cxcl12
Gagtm/Gagtm 
animals thus 
brings a new light to the original evidence that, beyond CXCL12-induced receptor cell 
signalling, the endogenous CXCL12/GAG interactions play a critical role  in tissue 
regeneration and in particular in vascular growth. Indeed, the efficiency of CXCL12# to 
rescue the default in Cxcl12
Gagtm/Gagtm 
animals contrasts with the lack of effect of CXCL12#m2 
and reveals the key role of this mechanism in the reparative process. This finding is in 
keeping with the efficiency of CXCL12# and the inability of CXCL12#m2 to promote homing 
of BM-derived circulating inflammatory cells and of circulating EPC into ischemic tissues, 
and modulate vessel growth in this setting.  
Bound to HS-structures on the apical surface of endothelial cells 
47
, CXCL12 expressed by 
autocrine or juxtacrine mechanisms could be determinant for vascular targeting of circulating 
progenitor and inflammatory cells and induction, in an integrin- and CXCR4-dependent 
manner, of both firm adhesion and transendothelial migration of infiltrating BM-derived cells 
48
. Among CXCL12 isoforms, CXCL12# binds to microvascular endothelial cell surface with 
the highest efficiency 
13
 
47
 and is ideally suited to accomplish this role. Abundantly expressed 
and induced in injured tissues by hypoxia, CXCL12# could delimit a static field of chemokine 
keeping cells motile (haptokinesis) in a restrained tissue compartment. This may contribute to 
the reparative effect of EPC by enhancing cell-adhesiveness and survival
49
. It could be 
hypothesized that, released progressively upon cleavage of its C-ter domain the pool of 
immobilized CXCL12# could provide a gradient of active, diffusible chemokines that would 
promote long-range chemotaxis toward the injured tissue. An analogous mechanism 
contributes to the regulation by CCL21 of lymphocyte T cell homing in secondary lymphoid 
organs 
1
. 
Regarding the potential of CXCL12 in regenerative medicine, the continuous delivery or 
administration in an immobilized form of CXCL12! is required to provide therapeutic effect 
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in post-ischemic treatment
50
. CXCL12# could overcome this limitation thus activating 
efficiently the pro-angiogenic mechanisms.  
Collectively, our findings unravel the contribution of endogenous CXCL12/HS complexes to 
the biological functions of this chemokine. The prevalence of CXCL12# expression in 
hypoxic conditions and its superior capacity to promote neovascularisation further highlights 
the importance of HS-binding mechanisms in the tissue reparative activity of CXCL12. 
The findings of this work pave the way for investigating the contribution of CXCL12/HS 
interactions to other homeostatic and physio-pathological functions played by this unique 
chemokine and could have broad relevance eventually for other chemokine systems. 
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FIGURE LEGENDS 
Figure 1. Characterization of Cxcl12
Gagtm/Gagtm 
mice. (A) Schematic representation of 
Cxcl12 genomic locus, targeting vector and recombined Cxcl12 locus (Cxcl12
Gagtm
). Exons 1-
4 are represented by darked boxes. Mutations incorporating residue substitutions (2
nd
 exon) 
and stop codon (4
th
 exon) are indicated by vertical arrows and stars. The LoxP-FRT-Neo 
cassette is inserted in an opposite orientation regarding to the target gene in intron 3-4. Long 
(LA) and short (SA) homology arm positions and length are indicated. (B) Hematoxylin and 
eosin staining of bone marrow (left panels), cerebellum (middle panels) and skeletal muscle 
(right panels) tissue sections from Cxcl12
Gagtm/Gagtm
 (MUT) and wild-type littermate (WT) 
animals. Arrows show megakaryocytes; 1 display white substance; 2, granular layer; 3, 
molecular layer. (C) Real-time PCR analysis of Cxcl12. Relative RNA expression levels of 
Cxcl12 isoforms normalized to HPRT in cerebellum, bone marrow and skeletal muscle 
tissues. Cxcl12!, Cxcl12" and Cxcl12# ARN levels on MUT animals are expressed relative to 
the WT animals level, arbitrary set to 1 (n=12 per group). (D). CXCL12 levels in blood were 
measured by ELISA in MUT and WT animals. (E) Cell populations in peripheral blood 
collected from MUT and WT animals. Results are mean±SEM. **p<0.01, ***p<0.001 versus 
WT. 
 
Figure 2. Expression of CXCL12 isoforms in ischemic tissue. (A) Quantitative evaluation 
and relative levels of CXCL12%, CXCL12& and CXCL12$ mRNA contents 1, 4, 6 and 21 
days after ischemia in ischemic and non ischemic legs of Cxcl12
Gagtm/Gagtm
 (MUT) and wild-
type littermate (WT) animals. Values are mean ± SEM. n=10/group, representative of 2 
independent experiments. 28 possible comparisons for Bonferroni correction, a value of 
p<0.0018 was considered significant, **p<0.0003 versus N Isch at day 1. (B) mRNA levels of 
each Cxcl12 isoform were normalized to that of Cxcl12! in skeletal muscle of non ischemic 
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tissue. 6 possible comparisons for Bonferroni correction, a value of p<0.008 was considered 
significant, n=10 per group. (C-D) Histological sections from ischemic skeletal muscles of 
WT and MUT animals showing CXCL12 expression in capillary (c) and arteriolar (d) 
structures. Red staining, alpha smooth muscle actin (alpha smooth muscle cells); green 
staining, Griffonia Simplicifolia Agglutinin isolectin B4 (endothelial cells); purple staining, 
CXCL12. Nuclei were stained with DAPI (blue staining). Bars: 10"m. One representative 
experiment out of six is shown. 
 
Figure 3. Postischemic revascularization in Cxcl12
Gagtm/Gagtm 
animals. Quantitative 
evaluation and representative photomicrographs of foot perfusion at different time points (A), 
and at day 21, for angiographic score (B, vessels in white), capillary density (C, capillaries in 
green, arrows show fibronectin–labelled capillaries), arteriole density (D, arterioles in green, 
arrows show %-actin –labelled arterioles) in Cxcl12
Gagtm/Gagtm
 (MUT) and wild-type littermate 
(WT) animals. Results are shown in ischemic (Isc) and non-ischemic (N.Isc) legs. D indicates 
day. Values are mean ± SEM. n = 15 per group, representative of 3 independent experiments. 
A) 15 possible comparisons for Bonferroni correction, a value of p<0.003 was considered 
significant, *p<0.03 and **p<0.0006 versus WT. B) 1 possible comparisons for Bonferroni 
correction, a value of p<0.05 was considered significant, ***p<0.001 versus WT. n = 15 per 
group. C-D) 6 possible comparisons for Bonferroni correction, a value of p<0.008 was 
considered significant, **p<0.0016 versus Isc WT. n = 15 per group. 
 
Figure 4. Quantification of infiltrating circulating cells in Cxcl12
Gagtm/Gagtm 
animals. 
Percentage of CD45.1+, CD45.1+/CD34+ and CD45.1+/CXCR4+ in blood (A) and ischemic 
muscle (B), 6 days after the onset of ischemia. Representative FACS dot plots obtained from 
WT and MUT digested muscle at 6 days after ischemia. Cells were gated on CXCR4 
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expressing CD45.1-positive cells. n = 7 per group. A-B) 1 possible comparisons for 
Bonferroni correction, a value of p<0.05 was considered significant. *p<0.05 versus WT. (C) 
Quantitative evaluation and representative photomicrographs of Mac3-positive cells 
(macrophages in brown, arrows show Mac-3 labelled macrophages) in Cxcl12
Gagtm/Gagtm
 
(MUT) and wild-type littermate (WT) animals. Results are shown in ischemic (Isc) and non-
ischemic (N.Isc) legs. Values are mean ± SEM. n = 15 per group, representative of 3 
independent experiments. 6 possible comparisons for Bonferroni correction, a value of 
p<0.008 was considered significant, **p<0.0016 versus Isc WT. 
 
Figure 5. Effect of CXCL12 isoforms on post-ischemic revascularization. Quantitative 
evaluation of foot perfusion (A), microangiography (B), capillary density (C), and arteriolar 
density (D) and macrophages infiltration (E), 21 days after ischemia in C57BL/6 mice 
transfected with empty DNA plasmid (CONT) or DNA expression vectors encoding 
CXCL12%, CXCL12$ or CXCL12#m2. Values are mean ± SEM. n = 15 per group, 
representative of 3 independent experiments. A-B) 6 possible comparisons for Bonferroni 
correction, a value of p<0.008 was considered significant, *p<0.008, **p<0.0016 versus PBS, 
! p<0.008 versus CXCL12%, #p<0.008, ##p<0.0016 versus CXCL12$. C-E) 28 possible 
comparisons for Bonferroni correction, a value of p<0.0017 was considered significant, 
*p<0.0017 versus Isc CONT, !p<0.0017 versus Isc CXCL12%, #p<0.0017 versus Isc 
CXCL12$. Isc indicates ischemic leg and N.Isc, non ischemic leg. 
 
Figure 6. CXCL12#  controls BM-derived cells infiltration in ischemic tissues. 
Quantitative evaluation and representative photomicrographs of the percentage of GFP-
expressing cells (A), GFP-expressing and BS1-labelled cells (B) and GFP-expressing and 
Mac3-labelled cells (C) in the ischemic leg of irradiated wild-type mice reconstituted with 
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bone marrow of WT GFP+ animals and treated with empty DNA plasmid (CONT), or DNA 
expression vectors encoding for CXCL12%, CXCL12$ or HS-binding mutant CXCL12#m2 . 
Value quantification are represented in histograms. Values are mean ± SEM. n = 10 per 
group, representative of 2 independent experiments. A-C) 28 possible comparisons for 
Bonferroni correction, a value of p<0.0017 was considered significant, *p<0.0017 versus Isc 
CONT, !p<0.0017 versus Isc CXCL12%, #p<0.0017 versus Isc CXCL12$. Isc indicates 
ischemic leg and N.Isc, non ischemic leg. 
 
Figure 7. CXCL12#  restores the defective angiogenic phenotype in Cxcl12Gagtm/Gagtm 
animals. Quantitative evaluation of foot perfusion (A), capillary density (B), arteriole density 
(C) and Mac3-positive cells (D) in Cxcl12
Gagtm/Gagtm 
(MUT) and wild-type littermate (WT) 
animals treated with or without DNA expression vector encoding CXCL12# . Results are 
shown in ischemic (Isc) and non-ischemic (N.Isc) legs. Values are mean ± SEM. n = 10 per 
group. A) 3 possible comparisons for Bonferroni correction, a value of p<0.016 was 
considered significant *p<0.016 versus WT. B-D) 15 possible comparisons for Bonferroni 
correction, a value of p<0.003 was considered significant. **p<0.0006 versus Isc WT, 
#p<0.003, ##p<0.0006 versus Isc MUT.  
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